Market Insights
A variety of life-threatening and chronic disorders, such as hematological diseases, immune deficiencies, genetic diseases, and neurological disorders, among others, are treated with plasma proteins. The different clinical responses of plasma proteins are due to their unique biochemical profile and variances in production and processing technologies. Recent developments observed in the plasma protein therapeutics industry are satisfactory and ground-breaking, especially the recently approved recombinant protein therapeutics, which cater to several clinical indications such as autoimmune diseases, cancers, infectious diseases, and genetic disorders.
These advancements in plasma protein therapeutics technologies have enabled industry players to maximize the therapeutic potential of proteins while maintaining product safety and efficacy. The key factors driving this market are the huge applications of immunoglobulins and albumin, which cater to a wide range of diseases; rising investment in research and development of novel plasma protein-based drugs; and increasing off-label use of immunoglobulins.
The global regulatory framework is evolving day by day with the incessant development of novel technologies in the biopharmaceutical industry. In the case of plasma protein therapeutics, improved versions of current therapies are being introduced that are mainly attained through enhanced drug targeting and enhancements in functionality and potency. Thus, the plasma protein therapeutics market is expected to experience tremendous growth in the near future.
North America was observed as the largest plasma protein therapeutics market due to the rising prevalence of chronic diseases, high acceptance and accessibility of novel drug therapy, and mounting investments in the R&D of plasma protein therapeutics. Asia Pacific was observed as the fastest-growing plasma protein therapeutics market due to rising demand for novel therapeutics, developing healthcare infrastructure, and the rising prevalence of cancer and autoimmune diseases.
New plasma-derived therapies entering the market are on the rise, which is the major factor assisting the overall market’s growth. On the other hand, major market restraints include stringent regulatory policies, evolving reimbursement policies for the developing plasma protein therapeutics industry, and intricacy in manufacturing.
The plasma protein therapeutics market is segmented on the following basis:
Product
- Immunoglobulins
- Albumin
- Coagulation Factors
- Alpha-1 Proteinase Inhibitor
- Other medications (C1-esterase Inhibitors and Hyperimmune Globulins)
Pipeline Analysis
- Analysis of Phase III Drugs, Forecast to 2026
- Phase II and Phase I (Tabular Representation)
Application
- Hemophilia
- Primary Immunodeficiency Disorder
- Idiopathic thrombocytopenic purpura
- Secondary Immunodeficiency
- Others (Kawasaki disease, hereditary angioedema, GBS, and CIDP)
Geography
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified for the plasma protein therapeutics market include:
Baxter International, GRIFOLS, S.A., Biotest, CSL Behring, Kedrion, Shire Plc., Octapharma USA, Inc., Telecris, and China Biologics
This report offers the following:
- The market assessment is done by furnishing the market size and compounded annual growth rate, considering 2017 as the base year and the period from 2018 to 2026 as the forecast period.
- For the geography, product, and application segments, an attractive investment proposition is given, which helps biopharmaceutical manufacturers to contemplate useful financial decisions.
- The competitive landscape helps in determining the competitive milieu currently existing in the plasma protein therapeutics market.
- The financial health of leading players is considered in the financial information segment, and a diverse range of plasma proteins is covered in the product portfolio section. Recent news coverage keeps us informed regarding the latest strategic developments and their impact on the plasma protein therapeutics market.
